Just published by "Science Daily" and featured on Google finance about Insmed. Yahoo won't let me post a link. Go to Google to find article. Very promising.
"June 25, 2013 — Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model. The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases..."
Your guess is as good as mine. However, will Insmed have to say anything at this time? It doesn't appear to be an Insmed study. Right now their priority is Arikace. But, I'm still excited by iPlex.
"remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. "
Sentiment: Strong Buy
Here is more from the Oxford Journals:
Triggering Regeneration and Tackling Apoptosis: A Combinatorial Approach to Treating MDC1A
Received April 5, 2013.
Revision received June 7, 2013.
Accepted June 11, 2013
"To accomplish this task we generated Bax-null Lama2Dy-wmice that overexpressed muscle specific IGF-1 (Lama2Dy-wBax−/-+IGF-1tg). Further to test the translational potential of IGF-1 administration in combination with Bax inhibition, we treated Lama2Dy-wBax−/-mice postnatally with systemic recombinant human IGF-1 (IPLEXTM). These two combinatorial treatments lead to similar, promising outcomes.
In addition to increased body and muscle weights, both transgenic overexpression and systemic administration of IGF-1 combined with Bax-inhibition resulted in improved muscle phenotype and locomotory function that were nearly indistinguishable from wild type mice. These results provide a fundamental proof-of-concept that justifies the use of a combination therapy as an effective treatment for MDC1A, and highlights a compelling argument towards shifting the paradigm in treating multifaceted neuromuscular diseases."
"shifting the paradigm in treating multifaceted neuromuscular diseases."
Why no PR from Insmed yet?
An excerpt from the article:
"The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc)."
More excerpt,. Note their words: "remarkable improvement in in muscle pathology..."
"By combining these two therapies [one of which is IPLEX], researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
Research highlighted in this news release was funded in part by Cure CMD, Struggle against Muscular Dystrophy (S.A.M), and the Muscular Dystrophy Association (MDA)."